Panaspar, 316 mg+280 mg 50 pcs.

To eliminate potassium and magnesium deficiency in combination therapy for various manifestations of coronary heart disease (including acute myocardial infarction);

Indications

To eliminate potassium and magnesium deficiency as part of combination therapy for various manifestations of coronary heart disease (including acute myocardial infarction);

Pharmacological effect

Pharmacodynamics

Special instructions

Patients with diseases accompanied by hyperkalemia require special attention: regular monitoring of potassium levels in the blood plasma is necessary.

Active ingredient

Potassium aspartate, Magnesium aspartate

Composition

Active ingredients:
Dosage
158 mg + 140 mg
Dosage
516 mg + 280 mg
Potassium aspartate hemihydrate
– 166.30 mg
– 332.60 mg
in terms of potassium aspartate
– 158.00 mg
– 316.00 mg
Magnesium aspartate tetrahydrate
– 175.00 mg
– 350.00 mg
in terms of magnesium aspartate
– 140.00 mg
– 280.00 mg
Excipients:
Corn starch
– 86.10 mg
– 172.20 mg
Potato starch
– 3.30 mg
– 6.60 mg
Silicon dioxide colloidal
– 2.00 mg
– 4.00 mg
Talc
– 10.00 mg
– 20.00 mg
Magnesium stearate
– 4.00 mg
– 8.00 mg
Povidone (polyvinylpyrrolidone
medium molecular weight, povidone K-30)
– 3.30 mg
– 6.60 mg
Core mass
450.0 mg
900.0 mg
Shell:
Hypromellose
(hydroxypropyl methylcellulose 6 cP)
– 3.785 mg
– 7.570 mg
Triacetin
– 0.380 mg
– 0.760 mg
Butyl methacrylate copolymer
-7.715 mg
– 15.430 mg
Titanium dioxide
– 1.925 mg
– 3.850 mg
Talc
– 2,260 mg
– 4.520 mg
Stearic acid
– 1,160 mg
– 2.320 mg
Sodium lauryl sulfate
– 0.775 mg
– 1,550 mg
Weight of coated tablet
film-coated
468.0 mg
936.0 mg

Pregnancy

Use is possible if the potential benefit to the mother outweighs the possible risk to the fetus.

Contraindications

Hypersensitivity to any of the constituent components of the drug, acute and chronic renal failure, hyperkalemia, hypermagnesemia, Addison’s disease, atrioventricular block I-III degree, shock (including cardiogenic) (blood pressure less than 90 mmHg), amino acid metabolism disorder, myasthenia gravis, hemolysis, acute metabolic acidosis, dehydration state, age under 18 years (efficacy and safety have not been established).

Side Effects

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the epigastric region (in patients with anacid gastritis or cholecystitis), atrioventricular block, paradoxical reaction (increased number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnesemia (facial redness, thirst, decreased blood pressure, hyporeflexia, respiratory depression, convulsions).

Interaction

Pharmacodynamic interaction

Overdose

The risk of symptoms of hyperkalemia and hypermagnesemia increases.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children!

Shelf life

2 years.

Manufacturer

Pharmstandard-Leksredstva, Russia